{"id":482825,"date":"2021-04-27T16:33:32","date_gmt":"2021-04-27T20:33:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/"},"modified":"2021-04-27T16:33:32","modified_gmt":"2021-04-27T20:33:32","slug":"sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/","title":{"rendered":"Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting"},"content":{"rendered":"<h2>\nPresentations include initial results from preclinical studies of expanded pipeline programs in immune-mediated and metabolic diseases<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., April  27, 2021  (GLOBE NEWSWIRE) &#8212; Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics\u2122 platform, today announced that four abstracts were selected for presentation at the American Society of Gene and Cell Therapy (ASGCT) 24<sup>th<\/sup> Annual Meeting, which will take place virtually from May 11-14, 2021. Among the presentations, are initial results from the study of Sigilon\u2019s novel Shielded Living Therapeutics<sup>TM<\/sup> (SLTx) technology in animal models of immune-mediated hepatitis and hypoparathyroidism, which reflects the modularity and expansion of Sigilon\u2019s pipeline programs. Overall, SLTx demonstrated the potential to overcome limitations associated with current therapies for these immune-mediated and metabolic disorders.<\/p>\n<p>The presentations will be made available on the ASGCT website starting on May 11<sup>th<\/sup>, 2021 at 8:00 AM EDT. The posters will also be made available in the Publications section of Sigilon\u2019s corporate website following the presentations. \u00a0\u00a0\u00a0<\/p>\n<p>\n        <strong><br \/>\n          <u>POSTER PRESENTATION DETAILS<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Title:<\/strong>\u00a0\u201cA Scaled and Semi-Automated Cell Encapsulation Process for a Shielded Cell-Based Platform for Chronic Diseases\u201d<br \/><strong>Abstract Number:<\/strong> 865<br \/><strong>Session:<\/strong> 531 \u2013 Cell Therapy Product Engineering, Development or Manufacturing<\/p>\n<p>\n        <strong>Title:\u00a0<\/strong>\u201cContinuous Delivery of IL-10 Using the Shielded Living Therapeutics<sup>TM<\/sup> Platform Leads to Modulation of Immune Cell Function and Prevents Liver Damage in Preclinical Model of Immune-Mediated Hepatitis\u201d<br \/><strong>Abstract Number:<\/strong> 704<br \/><strong>Session:<\/strong> 523 \u2013 Hematologic and Immunologic Diseases<\/p>\n<p>\n        <strong>Title:<\/strong>\u00a0\u201cTunable Delivery of Parathyroid Hormone with the Shielded Living Therapeutics<sup>TM<\/sup> Platform Provides a New Modality for Treatment of Hypoparathyroidism\u201d<br \/><strong>Abstract Number:<\/strong> 510<br \/><strong>Session:<\/strong> 512 \u2013 Metabolic, Storage, Endocrine, Liver and Gastrointestinal Disease<\/p>\n<p>\n        <strong>Title:<\/strong>\u00a0\u201cAnalytical Development Considerations for the Shielded Living Therapeutics<sup>TM<\/sup> Platform: A Novel Encapsulated Cell-Based, Non-Viral Platform for Delivery of Therapeutic Proteins\u201d<br \/><strong>Abstract Number:<\/strong> 864<br \/><strong>Session:<\/strong> 531 \u2013 Cell Therapy Product Engineering, Development or Manufacturing<\/p>\n<p>\n        <strong>About Sigilon Therapeutics<\/strong>\n      <\/p>\n<p>Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics\u2122 platform. Sigilon\u2019s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. The engineered cells are protected by Sigilon\u2019s Afibromer\u2122 biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201ccould,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cforecast,\u201d \u201cgoal,\u201d \u201cproject,\u201d and other words of similar meaning. These forward-looking statements address various matters, including the modularity of our pipeline programs and our ability to overcome limitations associated with current therapies for immune-mediated and metabolic disorders. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, those related to our clinical and preclinical research, product candidates and the regulatory filings related thereto, and the risks identified under the heading \u201cRisk Factors\u201d in our Annual Report on Form 10-K for the year ended December 31, 2020, and filed with the Securities and Exchange Commission, as well as the other information we file with the SEC. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4mMYEYNxE-iQecjl7tZn9rhgWdMW1KZE8sz5NscIfdqKgJ7oPlo8oNEAuKLtnlpFeiEPIWSEzgCkNMcWJAXJoA==\" rel=\"nofollow noopener\" target=\"_blank\">www.sec.gov<\/a>, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of these statements.\u00a0 Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.<\/p>\n<p>\n        <strong>SOURCE: Sigilon Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>\n        <strong>Investor Contacts<\/strong><br \/>\n        <br \/>Glenn Reicin<br \/>Sigilon Therapeutics, Chief Financial Officer<br \/>glenn.reicin@sigilon.com<br \/>646-696-4344<\/p>\n<p>Jennifer Porcelli<br \/>Solebury Trout<br \/>jporcelli@soleburytrout.com<br \/>646-378-2962<\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Amy Bonanno<br \/>Solebury Trout<br \/>abonanno@soleburytrout.com<br \/>914-450-0349<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDg3MiM0MTQyMzA1IzIxODExMTk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/39439ee8-6a0d-4c27-a94e-6d9e04e5d6d1\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Presentations include initial results from preclinical studies of expanded pipeline programs in immune-mediated and metabolic diseases CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) &#8212; Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics\u2122 platform, today announced that four abstracts were selected for presentation at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting, which will take place virtually from May 11-14, 2021. Among the presentations, are initial results from the study of Sigilon\u2019s novel Shielded Living TherapeuticsTM (SLTx) technology in animal models of immune-mediated hepatitis and hypoparathyroidism, which reflects the modularity and expansion of Sigilon\u2019s pipeline programs. Overall, SLTx demonstrated the potential to overcome limitations &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-482825","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Presentations include initial results from preclinical studies of expanded pipeline programs in immune-mediated and metabolic diseases CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) &#8212; Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics\u2122 platform, today announced that four abstracts were selected for presentation at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting, which will take place virtually from May 11-14, 2021. Among the presentations, are initial results from the study of Sigilon\u2019s novel Shielded Living TherapeuticsTM (SLTx) technology in animal models of immune-mediated hepatitis and hypoparathyroidism, which reflects the modularity and expansion of Sigilon\u2019s pipeline programs. Overall, SLTx demonstrated the potential to overcome limitations &hellip; Continue reading &quot;Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-27T20:33:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDg3MiM0MTQyMzA1IzIxODExMTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting\",\"datePublished\":\"2021-04-27T20:33:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\\\/\"},\"wordCount\":692,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDg3MiM0MTQyMzA1IzIxODExMTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\\\/\",\"name\":\"Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDg3MiM0MTQyMzA1IzIxODExMTk=\",\"datePublished\":\"2021-04-27T20:33:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDg3MiM0MTQyMzA1IzIxODExMTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDg3MiM0MTQyMzA1IzIxODExMTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting - Market Newsdesk","og_description":"Presentations include initial results from preclinical studies of expanded pipeline programs in immune-mediated and metabolic diseases CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) &#8212; Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics\u2122 platform, today announced that four abstracts were selected for presentation at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting, which will take place virtually from May 11-14, 2021. Among the presentations, are initial results from the study of Sigilon\u2019s novel Shielded Living TherapeuticsTM (SLTx) technology in animal models of immune-mediated hepatitis and hypoparathyroidism, which reflects the modularity and expansion of Sigilon\u2019s pipeline programs. Overall, SLTx demonstrated the potential to overcome limitations &hellip; Continue reading \"Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-27T20:33:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDg3MiM0MTQyMzA1IzIxODExMTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting","datePublished":"2021-04-27T20:33:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/"},"wordCount":692,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDg3MiM0MTQyMzA1IzIxODExMTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/","name":"Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDg3MiM0MTQyMzA1IzIxODExMTk=","datePublished":"2021-04-27T20:33:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDg3MiM0MTQyMzA1IzIxODExMTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDg3MiM0MTQyMzA1IzIxODExMTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sigilon-therapeutics-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-24th-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/482825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=482825"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/482825\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=482825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=482825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=482825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}